Pralatrexate is an antifolate for the treatment of relapsed or refractory peripheral T-cell lymphoma . Pralatrexate was developed in response due to the inferior responses of patients using the standard therapy for their B-cells counterparts. Compared to methotrexate, pralatrexate has better accumulation in cancer cells. Pralatrexate is designed to have a hi...
Pralatrexate is indicated for the treatment of relapsed or refractory peripheral T-cell lymphoma.
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.